138 related articles for article (PubMed ID: 25907064)
21. Knocking out salicylate biosynthesis genes in Mycobacterium smegmatis induces hypersensitivity to p-aminosalicylate (PAS).
Nagachar N; Ratledge C
FEMS Microbiol Lett; 2010 Oct; 311(2):193-9. PubMed ID: 20735479
[TBL] [Abstract][Full Text] [Related]
22. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
[TBL] [Abstract][Full Text] [Related]
23. Activity and interaction of trimethoprim and sulphamethoxazole against Escherichia coli.
Greenwood D; O'Grady F
J Clin Pathol; 1976 Feb; 29(2):162-6. PubMed ID: 777036
[TBL] [Abstract][Full Text] [Related]
24. Chronic granulomatous disease: effect of sulfamethoxazole/trimethoprim on neutrophil microbicidal function.
Seger RA; Baumgartner S; Tiefenauer LX; Gmünder FK
Helv Paediatr Acta; 1981; 36(6):579-88. PubMed ID: 7333866
[TBL] [Abstract][Full Text] [Related]
25. Emergence of high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim--sulfamethoxazole.
Murray BE; Rensimer ER; DuPont HL
N Engl J Med; 1982 Jan; 306(3):130-5. PubMed ID: 7033781
[TBL] [Abstract][Full Text] [Related]
26. Activity of trimethoprim (TMP), sulphamethoxazole (SMX) and the combination against Bacteroides fragilis group isolates.
Jackson-York GL; Gump BB; Gump DW
J Antimicrob Chemother; 1983 Nov; 12(5):515-8. PubMed ID: 6671927
[TBL] [Abstract][Full Text] [Related]
27. Regression-line analysis of trimethoprim-sulfamethoxazole activity against Neisseria gonorrhoeae.
Prior RB; Fass RJ; Perkins RL
Am J Clin Pathol; 1976 Sep; 66(3):605-9. PubMed ID: 822707
[TBL] [Abstract][Full Text] [Related]
28. Trimethoprim-resistant Enterobacteriaceae in urinary tract infection.
Wong CK; Harding GK; Ronald AR; Hoban S
Can Med Assoc J; 1975 Jun; 112(13 Spec No):54-8. PubMed ID: 1093652
[TBL] [Abstract][Full Text] [Related]
29. The use of trimethoprim-sulfamethoxazole in gonococcal infections.
Austin TW; Holmes KK
Can Med Assoc J; 1975 Jun; 112(13 Spec No):37-9. PubMed ID: 805648
[TBL] [Abstract][Full Text] [Related]
30. Pathogenic Nocardia cyriacigeorgica and Nocardia nova Evolve To Resist Trimethoprim-Sulfamethoxazole by both Expected and Unexpected Pathways.
Mehta H; Weng J; Prater A; Elworth RAL; Han X; Shamoo Y
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686152
[No Abstract] [Full Text] [Related]
31. Resistance among fecal flora of patients taking sulfamethoxazole-trimethoprim or trimethoprim alone.
Guerrant RL; Wood SJ; Krongaard L; Reid RA; Hodge RH
Antimicrob Agents Chemother; 1981 Jan; 19(1):33-8. PubMed ID: 7247360
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility of Stenotrophomonas maltophilia clinical strains in China to antimicrobial combinations.
Hu LF; Gao LP; Ye Y; Chen X; Zhou XT; Yang HF; Liiu YY; Mei Q; Li JB
J Chemother; 2014 Oct; 26(5):282-6. PubMed ID: 24588423
[TBL] [Abstract][Full Text] [Related]
33. Solubilities of trimethoprim and sulfamethoxazole at various pH values and crystallization of trimethoprim from infusion fluids.
McDonald C; Faridah
J Parenter Sci Technol; 1991; 45(3):147-51. PubMed ID: 1886043
[TBL] [Abstract][Full Text] [Related]
34. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes.
Toleman MA; Bennett PM; Bennett DM; Jones RN; Walsh TR
Emerg Infect Dis; 2007 Apr; 13(4):559-65. PubMed ID: 17553270
[TBL] [Abstract][Full Text] [Related]
35. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis.
Lelovic N; Mitachi K; Yang J; Lemieux MR; Ji Y; Kurosu M
J Antibiot (Tokyo); 2020 Nov; 73(11):780-789. PubMed ID: 32472054
[TBL] [Abstract][Full Text] [Related]
36. LC-MS based assay to measure intracellular compound levels in Mycobacterium smegmatis: linking compound levels to cellular potency.
Bhat J; Narayan A; Venkatraman J; Chatterji M
J Microbiol Methods; 2013 Aug; 94(2):152-158. PubMed ID: 23747411
[TBL] [Abstract][Full Text] [Related]
37. [Comparative activity of sulfamethoxazole-trimethoprim (SMZ-TMP) on bacteria responsible for ORL infections].
Joly B; Sirot D; Cluzel M; Chanal M; Bruneau D
Pathol Biol (Paris); 1984 Jun; 32(6):689-92. PubMed ID: 6611536
[TBL] [Abstract][Full Text] [Related]
38. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.
Grim SA; Rapp RP; Martin CA; Evans ME
Pharmacotherapy; 2005 Feb; 25(2):253-64. PubMed ID: 15767239
[TBL] [Abstract][Full Text] [Related]
39. Mycobacterium tuberculosis has diminished capacity to counteract redox stress induced by elevated levels of endogenous superoxide.
Tyagi P; Dharmaraja AT; Bhaskar A; Chakrapani H; Singh A
Free Radic Biol Med; 2015 Jul; 84():344-354. PubMed ID: 25819161
[TBL] [Abstract][Full Text] [Related]
40. Rifampin plus trimethoprim: bactericidal activity and suppression of resistance in human urine in vitro.
Goldstein BP; Ripamonti IF; Bolzoni G; Carniti G; Arioli V
Antimicrob Agents Chemother; 1979 Dec; 16(6):736-42. PubMed ID: 533255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
